Zentalis Pharmaceuticals, Inc.

What they do

Zentalis is focused on advancing azenosertib (ZN-c3), an oral small molecule WEE1 inhibitor, in Cyclin E1-positive platinum-resistant ovarian cancer (PROC). The company is conducting the DENALI Phase 2 trial and the ASPENOVA Phase 3 confirmatory trial. It is also evaluating azenosertib in combination with bevacizumab in the MUIR Phase 1 trial. Zentalis has no approved products and generates no revenue from product sales.

Revenue drivers

• No commercial products — Zentalis has no approved products and has not generated product revenue; it is a clinical-stage company.
• Collaboration revenue — The company reported $67.4 million in annual revenue for 2024, which may relate to collaborations, but no further details are provided.
• Future potential: azenosertib — Azenosertib is the only product candidate, with potential in PROC and other tumor types; no revenue is expected until regulatory approval.

Recent performance

For Q2 2026, Zentalis reported $174.6 million in cash, cash equivalents, and marketable securities as of June 30, 2026. The company had no revenue in any quarter of 2025. Net loss for 2025 was $137.1 million, with diluted EPS of $-1.91. Operating cash flow for 2025 was $-125.2 million. The balance sheet as of 2026-06-30 shows total assets of $215.3 million, total liabilities of $71.7 million, and shareholder equity of $143.6 million.

Strategy

Zentalis is prioritizing the rapid advancement of azenosertib toward first regulatory approval in Cyclin E1-positive PROC, with DENALI Part 2 intended to support accelerated approval. The company is also advancing ASPENOVA, a Phase 3 confirmatory trial, and exploring azenosertib in combination with other therapies and in earlier lines of ovarian cancer. Management is selectively evaluating new collaborations and strategic opportunities to maximize pipeline value. The strategy includes working with a diagnostic partner to validate a companion diagnostic for Cyclin E1 overexpression.

Risks

• No approved products — Zentalis has no products approved for commercial sale and has not generated product revenue, making it difficult to evaluate future success.
• Clinical trial failure risk — The success of azenosertib depends on positive results from the DENALI Part 2 trial; if unsuccessful, approval may not be obtained.
• Need for additional capital — Zentalis has significant ongoing losses and may need to raise additional capital, with cash runway only into late 2027.
• Competitive landscape — PROC patients have limited options, but existing treatments and competing investigational therapies could impact azenosertib's market potential.

Outlook

Management expects to report topline data from the DENALI Part 2 trial in the first half of 2027. Enrollment is complete for Parts 2a and 2b, with Part 2c currently enrolling. ASPENOVA Phase 3 trial is enrolling, with the first patient dosed in May 2026. The company expects cash to support execution of key milestones into late 2027.